Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6349419 | 0.93 | TUBB1 (0.43) | TUBB1ABCG2MAPTMEN1KMT2A | |
| SCHEMBL6352862 | 0.91 | TUBB1 (0.49) | TUBB1ABCG2MAPTMEN1KMT2A | |
| SCHEMBL6612326 | 0.90 | TUBB1 (0.44) | TUBB1MAPTHSD17B10PDE4APDE4B | |
| SCHEMBL6598545 | 0.86 | TUBB1 (0.47) | TUBB1HSD17B10PDE4APDE4BPDE4C | |
| SCHEMBL6355477 | 0.86 | TUBB1 (0.60) | TUBB1ABCG2MAPTMEN1KMT2A | |
| SCHEMBL6349594 | 0.86 | TUBB1 (0.48) | TUBB1ABCG2MAPTPDE4APDE4B | |
| SCHEMBL6599908 | 0.85 | TUBB1 (0.43) | TUBB1HSD17B10PDE4APDE4BPDE4C | |
| SCHEMBL6346903 | 0.85 | TUBB1 (0.46) | TUBB1ABCG2MAPTMEN1KMT2A | |
| SCHEMBL6349000 | 0.85 | TUBB1 (0.46) | TUBB1ABCG2MAPTMEN1KMT2A | |
| SCHEMBL6349801 | 0.85 | TUBB1 (0.48) | TUBB1ABCG2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203170-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | AVENTIS PHARMA S.A. | 2005-09-15 | — | — | US | disclosed |
| US-20040147584-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-07-29 | — | — | US | disclosed |
| US-20030153611-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | AVENTIS PHARMA S.A. | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147584-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | MCL1, ENPP1, MYC | TUBB1 2020/4885ABCG2 3826/4885MAPT 4182/4885 |
| US-20050203170-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | MCL1, ENPP1, MYC | TUBB1 2020/4885ABCG2 3826/4885MAPT 4182/4885 |
| US-20030153611-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | MCL1, ENPP1, MYC | TUBB1 2020/4885ABCG2 3826/4885MAPT 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.